04-01-2018 дата публикации
Номер: US20180000822A1
Принадлежит:
The present invention relates to the use of an agent that inhibits the activity of an enzyme that mediates repair of a DNA strand break in the manufacture of a medicament for the treatment of diseases caused by a defect in a gene that mediates homologous recombination. 132-. (canceled)33. A method of treatment of cancer cells defective in homologous recombination (HR) in a human patient , the method comprising;administering to the patient a therapeutically effective amount of a compound which inhibits PARP-1.34. The method of wherein the PARP inhibitor is selected from the group consisting of benzimidazole-carboxamides claim 33 , quinazolin-4-[3H]-ones and isoquinolone derivatives.35. The method of wherein the PARP inhibitor is selected from the group consisting of 2-(4-hydroxyphenyl)benzimidazole-4-carboxamide claim 34 , 8-hydroxy-2-methylquinazolin-4-[3H]one claim 34 , 6(5H)phenanthridinone claim 34 , 3-aminobenzamide claim 34 , benzimidazole-4-carboxamides and tricyclic lactam indoles.36. The method of wherein the cancer cells have defect in a gene encoding a protein involved in HR.37. The method of wherein the human patient has one functional allele of said gene claim 36 , said functional allele being lost in the cancer cells.38. The method of wherein the gene encoding a protein involved in HR is selected from the group consisting of XRCC1 claim 33 , CTPS claim 33 , RPA claim 33 , RPA1 claim 33 , RPA2 claim 33 , RPA3 claim 33 , XPD claim 33 , ERCC1 claim 33 , XPF claim 33 , MMS19 claim 33 , RAD51 claim 33 , RAD51B claim 33 , RAD51C claim 33 , RAD51D claim 33 , DMC1 claim 33 , XRCC2 claim 33 , XRCC3 claim 33 , BRCA1 claim 33 , BRCA2 claim 33 , RAD52 claim 33 , RAD54 claim 33 , RAD50 claim 33 , MRE11 claim 33 , NBS1 claim 33 , WRN claim 33 , BLM claim 33 , Ku70 claim 33 , Ku80 claim 33 , ATM claim 33 , ATR claim 33 , chkl claim 33 , chk2 claim 33 , FANCA claim 33 , FANCB claim 33 , FANCC claim 33 , FANCD1 claim 33 , FANCD2 claim 33 , FANCE claim 33 , FANCF claim ...
Подробнее
